Mirabegron Heumann

Mirabegron, the active ingredient in Mirabegron Heumann, is a β3‑adrenergic receptor agonist presented as a tablet for oral use. It treats overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is a β3‑adrenergic receptor agonist used in the management of overactive bladder.

Overactive bladder: improves bladder storage capacity and reduces urgency episodes. Urinary urgency: lessens the frequency of sudden urges to void. Urge urinary incontinence: decreases episodes of involuntary leakage. Urinary frequency: reduces the number of daytime voids.

Common Side Effects: - Hypertension: elevated blood pressure may be observed. - Headache: mild to moderate headache is reported. - Nasopharyngitis: upper‑respiratory tract infection symptoms. - Constipation: reduced bowel motility.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat requiring urgent care. - Severe hypertension: markedly high blood pressure needing medical intervention. - Urinary retention: difficulty emptying the bladder that may need catheterisation.

Precautions should be observed before initiating therapy.

Monitor blood pressure: check regularly as Mirabegron can raise systolic values. Assess cardiovascular status: use cautiously in patients with uncontrolled hypertension. Evaluate renal function: dose may need adjustment in severe renal impairment. Review concomitant medications: avoid strong CYP2D6 or CYP3A4 inhibitors where possible. Store at ambient temperature: keep below 25°C, retain in the original pack and protect from moisture.

Potential drug interactions require careful review.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase Mirabegron exposure (e.g., fluoxetine, paroxetine). - Potent CYP3A4 inhibitors: can raise plasma levels (e.g., ketoconazole, itraconazole). - Other β3‑adrenergic agonists: additive pharmacologic effect.

Moderate Interactions (Monitor Closely): - Diuretics: may amplify blood‑pressure changes. - Antihypertensive agents: dose adjustments may be needed. - NSAIDs: concurrent use can increase risk of hypertension.